Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Neurodegenerative Diseases Progression Markers (MARKERS-NDD)

Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders - Patients with diagnosis of Parkinson's Disease - Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank - Diagnosis of Movement Disorder not related to Parkinson's Disease - Diagnosis of Multiple System Atrophy (MSA) in accordance with Second Consensus Statement on Diagnosis of Multiple System Atrophy; - Diagnosis of Progressive Supranuclear Palsy according to Movement Disorder Society for Diagnosis of Progressive Supranuclear Palsy; - Diagnosis of Essential Tremor - Willing to participate in the study, understand the procedures and sign the willing to sign a consent form. - Patients affected by cognitive impairment (CI) and dementia - Diagnosis of probable: - Lewy Body Dementia - Alzheimer's Disease - Mild Cognitive Decline - Subjective memory complaints - Willing to participate in the study, understand the procedures and sign the willing to sign a consent form. Who Should NOT Join This Trial: - There are no restrictions for participation in the study based on age, severity of illness or presence of cognitive impairment, as long as the person is able to complete the research assessments. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders * Patients with diagnosis of Parkinson's Disease * Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank * Diagnosis of Movement Disorder not related to Parkinson's Disease * Diagnosis of Multiple System Atrophy (MSA) in accordance with Second Consensus Statement on Diagnosis of Multiple System Atrophy; * Diagnosis of Progressive Supranuclear Palsy according to Movement Disorder Society for Diagnosis of Progressive Supranuclear Palsy; * Diagnosis of Essential Tremor * Willing to participate in the study, understand the procedures and sign the informed consent. * Patients affected by cognitive impairment (CI) and dementia * Diagnosis of probable: * Lewy Body Dementia * Alzheimer's Disease * Mild Cognitive Decline * Subjective memory complaints * Willing to participate in the study, understand the procedures and sign the informed consent. Exclusion Criteria: * There are no restrictions for participation in the study based on age, severity of illness or presence of cognitive impairment, as long as the person is able to complete the research assessments.

Treatments Being Tested

OTHER

Observation

In MARKERS-NDD up to 600 participants will be enrolled and followed longitudinally once identified, over the course of 1-10 years

Locations (1)

San Raffaele Cassino
Cassino, Frosinone, Italy